MBX

MBX Biosciences (MBX)

About MBX Biosciences (MBX)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Details

Daily high

$28.50

Daily low

$27.04

Price at open

52 Week High

$34.83

52 Week Low

$4.81

Market cap

1.2B

Dividend yield

0.00%

Volume

226

Avg. volume

766,277

P/E ratio

-11.59

MBX Biosciences News